HC Wainwright Has Positive Outlook for Precigen Q3 Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Precigen to $0.05 from $0.01, while maintaining a Buy rating and an $18 price target. The broader analyst consensus remains Hold, with a $14.50 average price target.
• Precigen’s latest quarterly results exceeded expectations, with EPS of $0.05 versus a projected loss of $0.01 and revenue of $54.98 million versus $27.98 million expected. Revenue increased more than 6,300% year over year, driven by PAPZIMEOS.
• Precigen shares opened at $6.91, near their 52-week high of $7.23, while insiders sold approximately $5.25 million of stock over the past 90 days under pre-arranged trading plans.

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Analysts at HC Wainwright boosted their Q3 2026 earnings per share (EPS) estimates for shares of Precigen in a research report issued on Wednesday, August 5th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings of $0.05 per share for the quarter, up from their previous estimate of $0.01. HC Wainwright has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.02) per share. HC Wainwright also issued estimates for Precigen's FY2026 earnings at $0.14 EPS.

Other analysts have also recently issued reports about the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Precigen in a research note on Friday, July 17th. Citizens Jmp increased their price objective on shares of Precigen from $9.00 to $11.00 and gave the stock a "market outperform" rating in a research note on Thursday, May 14th. Wall Street Zen cut shares of Precigen from a "buy" rating to a "hold" rating in a report on Sunday, May 31st. Finally, Citigroup reissued an "outperform" rating on shares of Precigen in a report on Thursday, May 14th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $14.50.

Precigen Price Performance

Shares of NASDAQ PGEN opened at $6.91 on Friday. Precigen has a 52 week low of $1.70 and a 52 week high of $7.23. The business's 50 day moving average price is $5.17 and its 200 day moving average price is $4.48. The company has a quick ratio of 4.12, a current ratio of 4.58 and a debt-to-equity ratio of 2.15. The firm has a market cap of $2.46 billion, a P/E ratio of -6.64 and a beta of 1.02.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.06. Precigen had a positive return on equity of 423.75% and a negative net margin of 183.98%.The firm had revenue of $54.98 million during the quarter, compared to analysts' expectations of $27.98 million. Precigen's revenue was up 6322.7% on a year-over-year basis.

Insider Buying and Selling

In other news, CFO Harry Jr. Thomasian sold 171,429 shares of the firm's stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $5.53, for a total transaction of $948,002.37. Following the sale, the chief financial officer owned 354,535 shares of the company's stock, valued at $1,960,578.55. This trade represents a 32.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Rutul R. Shah sold 42,924 shares of the firm's stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $5.85, for a total transaction of $251,105.40. Following the sale, the chief operating officer directly owned 497,751 shares in the company, valued at $2,911,843.35. The trade was a 7.94% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 956,500 shares of company stock valued at $5,248,371 in the last ninety days. Insiders own 41.40% of the company's stock.

Institutional Trading of Precigen

Hedge funds have recently added to or reduced their stakes in the company. SCS Capital Management LLC purchased a new position in Precigen in the second quarter valued at $244,000. Bank of New York Mellon Corp purchased a new stake in shares of Precigen during the 2nd quarter worth about $2,705,000. State of Wyoming purchased a new stake in shares of Precigen during the 2nd quarter worth about $181,000. GSA Capital Partners LLP acquired a new stake in shares of Precigen during the 2nd quarter valued at about $667,000. Finally, Royal Bank of Canada grew its position in shares of Precigen by 102.6% during the 1st quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 5,426 shares during the period. 33.51% of the stock is owned by hedge funds and other institutional investors.

Key Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong Q2 performance and profitability: Precigen reported that PAPZIMEOS revenue reached $53.1 million in the second quarter, roughly doubling sequentially. The company also achieved profitability, while earnings-call coverage highlighted a 145% increase in revenue. These results support the view that PAPZIMEOS is becoming a meaningful commercial product. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: Regulatory and commercial catalysts: FDA approval of PAPZIMEOS for recurrent respiratory papillomatosis, along with seven years of U.S. market exclusivity, strengthens the product’s revenue outlook. Potential European approval and expansion of Precigen’s AdenoVerse Immunotherapy platform—including PRGN-2009—could provide additional growth opportunities. Precigen Strong Buy and PAPZIMEOS Outlook
• Positive Sentiment: Analyst estimates moved higher: HC Wainwright reiterated its Buy rating and $18 price target, raising its FY2027 EPS forecast to $0.44 from $0.34. Estimates for Q4 2026 and each quarter of 2027 were also increased, while the FY2030 forecast rose to $1.49 from $1.44. These revisions signal greater confidence in the company’s earnings trajectory. HC Wainwright Reiterates Buy Rating for Precigen
• Neutral Sentiment: Unusually large options activity attracted attention, but the available report does not identify whether the transactions were bullish or bearish. Precigen Unusually Large Options Trading
• Negative Sentiment: One forecast was trimmed: HC Wainwright reduced its FY2028 EPS estimate slightly to $0.71 from $0.72, a minor offset to the broader upward revisions.

Precigen Company Profile

Precigen, Inc NASDAQ: PGEN is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen's approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen's technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source